RxDoctor Payments Data

Ravinder Bachireddy, MD

Interventional Cardiology · Lufkin, TXNPI 1023094703

Payments from drug & device makers

$148,481in general payments, 2019–2025

Across 169 payments — averaging $878.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$144K
  • Boston Scientific$2K
  • Medtronic$1K
  • Novartis$228
  • Abiomed$184
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$181
  • plus $925 from 11 others
$68,893in research payments, 2019–2025

Across 3 payments — averaging $22,964 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$69K

What the payments were for

  • Travel & lodging$3,06143%
  • Food & beverage$4,09957%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$148,481 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$661,601
Medicare patients
1,098
Services billed
8,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban664$590,201
XareltoRivaroxaban299$230,133
EntrestoSacubitril/Valsartan56$62,375
BrilintaTicagrelor47$32,319
Metoprolol Succinate1,173$23,574
Amiodarone Hcl287$8,192
Losartan Potassium389$4,963
ClopidogrelClopidogrel Bisulfate363$4,840
Amlodipine Besylate528$4,560
Isosorbide Mononitrate ErIsosorbide Mononitrate355$4,130
Potassium Chloride195$3,772
Metoprolol Tartrate334$2,891
Carvedilol300$2,808
Lisinopril310$2,210
Atorvastatin Calcium266$2,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$68$230,133299 claims
NovartisEntresto$228$62,37556 claims
AstraZenecaBrilinta$46$32,31947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →